

JPTA Symposium at CPHI Japan 2026

Navigating Japan's Evolving Pharmaceutical Regulatory Landscape: a Global API Manufacturer's perspective

Daniele Oldani

Sales & Business Development Manager

Icrom Business Unit | April 22nd 2026

Via delle Arti 33, 20863 Concorezzo, Italy

www.icrom.com; d.oldani@Icrom.com;

About Icom



Icom is a trusted Italian CDMO specialized in development and GMP manufacturing of hi-tech APIs.

Headquartered in Concorezzo (Monza), Icom supports pharma & biotech companies from early-development to commercial production.

- 50 years + in the pharma industry as CDMO and API manufacturer
- 2 R&D centers, 1 GMP Manufacturing site with 6 diversified production units
- Global presence in business operations in more than 30 Countries Worldwide

Experience in Japan

- Active collaborations with Japanese pharmaceutical partners
- Experience in Japanese regulatory pathways
- Engagement with evolving regulatory frameworks



This perspective provides a practical view on how the 2025 PMDA pharmaceutical reform may influence international pharmaceutical development and market access in Japan

Overview of Today's Discussion



- Context & Perspective
- Areas Where EU API Manufacturers Perceive Complexity
- Strategic Considerations for Global API Manufacturers
- Outlook: Opportunities for Further Collaboration
 - Possible areas for continued dialogue
 - Question for discussion
 - Closing

Context and Perspective

Japan as a high-quality, compliance-driven pharmaceutical market

- What Global Manufacturers Value About Japan:
 - Technical competence
 - High level of professionalism
 - Long-term relationships
 - Strong quality culture
- Within the evolving Yokki ho 2025 framework, and in comparison with some foreign guidelines (e.g. Italian standards), stakeholders note opportunities for regulatory alignment and simplification

Two Traditions of Harmony



different design, same purpose

Areas where EU API Manufacturers perceive complexity

Foreign Manufacturer Accreditation

- Accreditation process and timelines
- Perceived overlap with EU-GMP
- Post-approval changes
- Communication flow, documentation and language



Strategic Considerations for Global API Manufacturers

When evaluating long-term engagement in Japan, companies often evaluate:

- Market dynamics
- Operational complexity
- Investment required to serve the Japanese market
- Ability to maintain globally integrated supply chains



Outlook: Opportunities for Further Collaboration - 1

Possible areas for continued dialogue

Key Area	Stakeholder Perspective	Suggested Way Forward
Accreditation process	Timelines and procedural complexity remain a concern for stakeholders	Further alignment with ICH principles to support streamlined and predictable processes
Interaction with EU-GMP framework	Perceived overlap between accreditation requirements and EU-GMP expectations	Strengthened technical dialogue between API suppliers, MAHs, and competent authorities to clarify interfaces
Post-approval changes	Need for greater predictability in change management requirements	Clearer regulatory guidance and expectations for post-approval change management
Communication and documentation	Communication flows and documentation processes could be more efficient	Continued efforts towards transparency, improved communication channels, and further digitalization

Outlook: Opportunities for Further Collaboration - 2

Question for discussion

How can Japan remain highly rigorous while facilitating broader global participation?



Closing

Global manufacturers do not seek lower standards but greater predictability, proportionality, and dialogue.

Thank you for your attention
*with special thanks to the organizers,
coordinators and audience*



Daniele Oldani

Sales & Business Development Manager

Icrom Business Unit | April 22nd 2026

Via delle Arti 33, 20863 Concorezzo, Italy

www.icrom.com; d.oldani@Icrom.com;